February 10, 2021 -- The U.S. Patent and Trademark Office has granted a patent to Bio-Path Holdings for its nucleic acid drug platform, expanding protections for the company's DNAbilize technology.
Bio-Path was awarded U.S. patent No. 10,898,506 titled, "P-ethoxy nucleic acids for liposomal formulation."
On February 23, the company expects to be issued U.S. patent No. 10,927,379 for its lead product candidate prexigebersen, a liposomal formulation containing the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2 (Grb2).